Loading data for FATE — first visit, this takes a few seconds.
Fate Therapeutics Inc. (FATE)
NasdaqGM: FATE
· Real-Time Price · USD
2.65
+0.09 (3.52%)
At close: Aug 20, 2026, 6:19 PM
The price, the headline numbers and the latest news, in one place.
Fate Therapeutics Inc. (FATE) Stock Price, Analysis & Data
3.52% (1D)
No data available
| Bid | 1.91 |
| Market Cap | 295.36M |
| Revenue (ttm) | 6.49M |
| Net Income (ttm) | -126M |
| 2.55 | |
| -1.09 | |
| n/a | |
| -2.52 | |
| P/B (ttm) | 1.87 |
| P/S (ttm) | 45.50 |
| Earnings Date | Nov 12, 2026 |
| Ask | 3.28 |
| Volume | 1,163,445 |
| Avg. Volume (20D) | 3,675,537 |
| Open | 2.61 |
| Previous Close | 2.56 |
| Day's Range | 2.59 - 2.70 |
| 52-Week Range | 0.93 - 3.23 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat sys...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2013
Employees 161
Stock Exchange NasdaqGM
Ticker Symbol FATE
Website https://www.fatetherapeutics.com
Financial Performance
In 2025, Fate Therapeutics's revenue was 6.65M, a decrease of -51.24% compared to the previous year's 13.63M. Earnings were -136.31M, a decrease of -26.82%.
Financial StatementsEarnings Surprise
Fate Therapeutics has released their quarterly earnings on Aug 13, 2026:
Fate Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2